For plaque or guttate psoriasis, home-based narrowband ultraviolet B phototherapy is as effective as office-based ...

The FDA approval of Otulfi™, Fresenius Kabi’s fourth biosimilar product in the U.S. market, is an important milestone on our pathway to consistently broadening our biopharma portfolio in the U.S. and ...

UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with ...

This is what we know about psoriasis so far, and how you can manage it at home. Psoriasis is a chronic skin condition that manifests in different forms. These include plaque psoriasis, guttate ...

The NDA submission is backed by results from a study that enrolled 604 adults from China who have stable plaque psoriasis.

Regulatory Approval/Market LaunchFormycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz) 30.09.2024 / 07:30 CET/CESTThe issuer is solely responsible for the content of ...

Zasocitinib demonstrates effectiveness and safety in the treatment of moderate to severe plaque psoriasis, according to study results published in JAMA Dermatology ... [Z]asocitinib…achieved ...

Fresenius Kabi, in partnership with Formycon AG, has received European Commission approval for Otulfi®, a biosimilar of ...

LEO Pharma A/S, a global leader in medical dermatology, has today announced its submission of a New Drug Application (NDA) to ...

Plaque psoriasis, the most common form of psoriasis (about 90 per cent of cases), is a chronic inflammatory autoimmune ...